About Us
Serina Therapeutics, Inc. was founded in 2007 by Drs. Milton Harris and Michael Bentley. The intent of the company is to develop a proprietary polymer technology that
- is readily available from safe, water-soluble starting materials;
- will allow for attachment of any class of therapeutic molecule to its backbone through specific chemical pendants; and
- will retain a targeting moiety to allow the polymeric compound to be actively targeted to specific receptors in the body.
Polyoxazoline (POZ) was chosen as the polymer since it had all of the above properties. After a four-year technology development phase, during which Serina perfected the composition and production of its polymer platform, the company advanced its first lead clinical candidate, SER-203, into IND-enabling studies in 2011.
Serina's technology platform is very broad; it allows for the attachment of any class of potential therapeutic molecules to its polymer backbone, and the attachment of specific targeting moieties can direct the resultant polymeric compounds to specific sites and receptors in the body.
Serina Therapeutics, Inc. is located on the campus of the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. The HudsonAlpha Institute is an incubator campus for companies with exceptional promise in the areas of research genetics, diagnostics, therapeutics, gene therapy and pharmaceutical drug development.
